This compound also has a picomolar binding affinity and inhibits the proliferation of MYC-induced cancer cells (neuroblastoma and Burkitt’s lymphoma) and MLL1-rearranged leukemia by reducing MYC recruitment to the MYC/WDR5 target gene. Here, KMT2A is linked to leukemia.